



c4-06-07

Din

PTO/SB/21 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)


TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/812,636-Conf. #3487
	Filing Date	March 29, 2004
	First Named Inventor	Nehal MOHAMED
	Art Unit	1645
	Examiner Name	K.S. Shahnan Shah
Total Number of Pages in This Submission	Attorney Docket Number	ELI-029

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Receipt Postcard PTO form SB/08 Certificate of Mailing Copies of Thirty-one (31) References
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	LAHIVE & COCKFIELD, LLP		
Signature			
Printed name	Megan E. Williams		
Date	April 5, 2007	Reg. No.	43,270



Application No. (if known): 10/812,636

Attorney Docket No.: ELI-029

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV 956473947 US in an envelope addressed to:

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on April 5, 2007
Date

Signature

Megan E. Williams

Typed or printed name of person signing Certificate

43,270
Registration Number, if applicable

(617) 227-7400
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Return Receipt Postcard
Transmittal (1 page)
Information Disclosure Statement (2 pages)
PTO form SB/08 (41 References) (3 pages)
Copies of Thirty-one (31) References

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Patent Application of:
Nehal Mohamed *et al.*

Application No.: 10/812,636

Confirmation No.: 3487

Filed: March 29, 2004

Art Unit: 1645

For: METHODS AND COMPOSITIONS FOR
CONVERSION OF ANTIBODY ACTIVITY

Examiner: K.S. Shahnan Shah

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT (IDS)

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicants have not submitted copies of U.S. patents and U.S. patent applications. Applicants submit herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information

as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.


It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. ELI-029.

Dated: April 5, 2007

MEW/MBC/mch

Respectfully submitted,

By 

Megan E. Williams

Registration No.: 43,270

LAHIVE & COCKFIELD, LLP

One Post Office Square

Boston, Massachusetts 02109-2127

(617) 227-7400

(617) 742-4214 (Fax)

Attorney/Agent For Applicants



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/812,636-Conf. #3487		
		Filing Date	March 29, 2004		
		First Named Inventor	Nehal MOHAMED		
		Art Unit	1645		
		Examiner Name	K.S. Shahnan Shah		
Sheet	1	of	3	Attorney Docket Number	ELI-029

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1*	US-4,474,893	10-02-1984	Reading	
	A2*	US-5,212,071	05-18-1993	Fearon et al.	
	A3*	US-5,470,570	11-28-1995	Taylor et al.	
	A4*	US-5,487,890	01-30-1996	Taylor et al.	
	A5*	US-5,798,229	08-25-1998	Strittmatter et al.	
	A6*	US-5,879,679	03-09-1999	Taylor et al.	
	A7*	US-5,959,084	09-28-1999	Ring et al.	
	A8*	US-6,316,604	11-13-2001	Fearon et al.	
	A9*	US-20020103343-A1	08-01-2002	Taylor et al.	
	A10*	US-6,479,729	11-12-2002	Campochiaro et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1	WO-92/05801-A1	04-16-1992	University of Virginia Patents Foundation		
	B2	WO-95/22977-A1	08-31-1995	University of Virginia Patents Foundation		
	B3	WO-01/45669-A1	06-28-2001	Elusys Therapeutics, Inc.		
	B4	WO-01/80883-A1	11-01-2001	Elusys Therapeutics, Inc.		
	B5	WO-02/46208-A2	06-13-2002	Elusys Therapeutics, Inc.		
	B6	WO-02/075275-A2	09-26-2002	Elusys Therapeutics, Inc.		
	B7	WO-03/007971-A1	01-30-2003	University of Virginia Patent Foundation		
	B8	WO-04/024889-A2	03-25-2004	Elusys Therapeutics, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Craig, Maria L. et al., "Infusion of Bispecific Monoclonal Antibody Complexes into Monkeys Provides Immunologic Protection against Later Challenge with a Model Pathogen," <i>Clinical Immunology</i> , Vol. 92(2):170-180 (1999)	
	C2	Edberg, J.C. et al., "Functional characterization of non-human primate erythrocyte immune adherence receptors: implications for the uptake of immune complexes by the cells of the mononuclear phagocytic system," <i>Eur. J. Immunol.</i> , Vol. 22(6):1333-1339 (1992)	

Examiner Signature	Date Considered
-----------------------	--------------------

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/812,636-Conf. #3487
				Filing Date	March 29, 2004
				First Named Inventor	Nehal MOHAMED
				Art Unit	1645
				Examiner Name	K.S. Shahnan Shah
Sheet	2	of	3	Attorney Docket Number	ELI-029

C3	Hahn, Chang S. et al., "Bispecific Monoclonal Antibodies Mediate Binding of Dengue Virus to Erythrocytes in a Monkey Model of Passive Viremia," <i>The Journal of Immunology</i> , Vol. 166:1057-1065 (2001)	
C4	Henchal, E.A. et al., "Epitopic Analysis of Antigenic Determinants on the Surface of Dengue-2 Virions Using Monoclonal Antibodies," <i>Am. J. Trop. Med. Hyg.</i> , Vol. 34(1):162-169 (1985)	
C5	Klickstein, Lloyd B. et al., "Identification of Distinct C3b and C4b Recognition Sites in the Human C3b/C4b Receptor (CR1, CD35) by Deletion Mutagenesis," <i>J. Exp. Med.</i> , Vol. 168:1699-1717 (1988)	
C6	Kuhn, Susan E. et al., " <i>Escherichia coli</i> Bound to the Primate Erythrocyte Complement Receptor via Bispecific Monoclonal Antibodies Are Transferred to and Phagocytosed by Human Monocytes in an In Vitro Model," <i>The Journal of Immunology</i> , Vol. 160:5088-5097 (1998)	
C7	Lindorfer, Margaret A. et al., "Heteropolymer-mediated clearance of immune complexes via erythrocyte CR1: mechanisms and applications," <i>Immunological Reviews</i> , Vol. 183:10-24 (2001)	
C8	Little, Stephen F. et al., "Production and Characterization of Monoclonal Antibodies to the Protective Antigen Component of <i>Bacillus anthracis</i> Toxin," <i>Infection and Immunity</i> , Vol. 56(7):1807-1813 (1988)	
C9	Mabry, Robert et al., "Protection Against Anthrax Toxin by Heteropolymers Directed Against Protective Antigen," <i>Abstracts of Papers American Chemical Society</i> , Vol. 225(1-2):124 (2003)	
C10	Nardin, A. et al., "A prototype pathogen bound ex vivo to human erythrocyte complement receptor 1 via bispecific monoclonal antibody complexes is cleared to the liver in a mouse model," <i>Eur. J. immunol.</i> , Vol. 29(5):1581-1586 (1999)	
C11	Nardin, A. et al., "How are immune complexes bound to the primate erythrocyte complement receptor transferred to acceptor phagocyte cells?" <i>Mol. Immunol.</i> , Vol. 36(13-14):827-835 (1999)	
C12	Nardin, A. et al., "Quantitative studies of heteropolymer-mediated binding of inactivated Marburg virus to the complement receptor on primate erythrocytes," <i>J. Immunol. Methods</i> , Vol. 211(1-2):21-31 (1998)	
C13	Nickells, M. et al., "Mapping epitopes for 20 monoclonal antibodies to CR1," <i>Clin. Exp. Immunol.</i> , Vol. 112:27-33 (1998)	
C14	Perez, P. et al., "Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody," <i>Nature</i> , Vol. 316(6026):354-356 (1985)	
C15	Powers, John H. et al., "Complement-Independent Binding of Microorganisms to Primate Erythrocytes In Vitro by Cross-Linked Monoclonal Antibodies via Complement Receptor 1," <i>Infection and Immunity</i> , Vol. 63(4):1329-1335 (1995)	
C16	Reilly, Brian D. et al., "Quantitative Analysis of C4b Dimer Binding to Distinct Sites on the C3b/C4b Receptor (CR1)," <i>The Journal of Biological Chemistry</i> , Vol. 269(10):7696-7701 (1994)	
C17	Reist, C.J. et al., "Antigens pre-bound to the primate erythrocyte complement receptor via cross-linked bispecific monoclonal antibody heteropolymers are rapidly cleared from the circulation," <i>Eur. J. Immunol.</i> , Vol. 23(11):3021-3027 (1993)	
C18	Roehrig, John T. et al., "Monoclonal Antibody Mapping of the Envelope Glycoprotein of the Dengue 2 Virus, Jamaica," <i>Virology</i> , Vol. 246:317-328 (1998)	
C19	Taylor, Ronald P. et al., "Bispecific Monoclonal Antibody Complexes Bound to Primate Erythrocyte Complement Receptor 1 Facilitate Virus Clearance in a Monkey Model," <i>The Journal of Immunology</i> , Vol. 158:842-850 (1997)	

Examiner Signature	Date Considered
-----------------------	--------------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/812,636-Conf. #3487
				Filing Date	March 29, 2004
				First Named Inventor	Nehal MOHAMED
				Art Unit	1645
				Examiner Name	K.S. Shahnan Shah
Sheet	3	of	3	Attorney Docket Number	ELI-029

	C20	Taylor, Ronald P. et al., "Bispecific Monoclonal Antibody Complexes Facilitate Erythrocyte Binding and Liver Clearance of a Prototype Particulate Pathogen in a Monkey Model," <i>The Journal of Immunotherapy</i> , Vol. 159:4035-4044 (1997)	
	C21	Taylor, Ronald P. et al., "Clearance of blood-borne pathogens mediated through bispecific monoclonal antibodies bound to the primate erythrocyte complement receptor," <i>Cancer Immunol. Immunother.</i> , Vol. 45:152-155 (1997)	
	C22	Taylor, Ronald P. et al., "In Vivo Binding and Clearance of Circulating Antigen by Bispecific Heteropolymer-Mediated Binding to Primate Erythrocyte Complement Receptor," <i>The Journal of Immunology</i> , Vol. 148(8):2462-2468 (1992)	
	C23	Taylor, Ronald P. et al., "Use of heteropolymeric monoclonal antibodies to attach antigens to the C3b receptor of human erythrocytes: A potential therapeutic treatment," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 88:3305-3309 (1991)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--